Table 3 Treatment-related adverse events (AE) experienced by the 7 patients in Cohort 4, treated at the MTD, who started treatment, by CTCAE grade.
No. of patients AE affected n, (%) | Any Grade (n = 7) | Grade 3 (n = 7) | Grade 4 (n = 7) |
|---|---|---|---|
NON-HAEMATOLOGICAL AND NON-BIOCHEMICAL | |||
Rash | 6 (86) | 0 (0) | 0 (0) |
Abdominal pain | 1 (14) | 1 (14) | 0 (0) |
Constipation | 1 (14) | 0 (0) | 0 (0) |
Diarrhoea | 3 (43) | 0 (0) | 0 (0) |
Fatigue | 3 (43) | 1 (14) | 0 (0) |
Anorexia | 1 (14) | 0 (0) | 0 (0) |
Nausea | 1 (14) | 0 (0) | 0 (0) |
Oedema | 2 (29) | 0 (0) | 0 (0) |
Paronychia | 1 (14) | 0 (0) | 0 (0) |
QTc prolongation | 1 (14) | 0 (0) | 0 (0) |
Visual disturbance | 1 (14) | 0 (0) | 0 (0) |
Vomiting | 2 (29) | 0 (0) | 0 (0) |
BIOCHEMICAL | |||
LDH increase | 1 (14) | 0 (0) | 0 (0) |
HAEMATOLOGICAL | |||
Thrombocytopenia | 1 (14) | 0 (0) | 0 (0) |
